Hospitalization following influenza infection and pandemic vaccination in multiple sclerosis patients: a nationwide population-based registry study from Norway.
Adult
Data Management
Female
Hospitalization
/ statistics & numerical data
Humans
Influenza A Virus, H1N1 Subtype
Influenza Vaccines
/ administration & dosage
Influenza, Human
/ complications
Male
Middle Aged
Multiple Sclerosis
/ epidemiology
Norway
/ epidemiology
Pandemics
Population Surveillance
/ methods
Registries
Risk Assessment
Vaccination
/ adverse effects
Hospitalization
Influenza
Multiple sclerosis
Norway
Pandemic
Pandemrix vaccination
Journal
European journal of epidemiology
ISSN: 1573-7284
Titre abrégé: Eur J Epidemiol
Pays: Netherlands
ID NLM: 8508062
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
22
08
2019
accepted:
05
12
2019
pubmed:
25
12
2019
medline:
27
5
2020
entrez:
25
12
2019
Statut:
ppublish
Résumé
Patients with multiple sclerosis (MS) are at increased risk of infections and related worsening of neurological function. Influenza infection has been associated with increased risk of various neurological complications. We conducted a population-based registry study to investigate the risk of acute hospitalization of MS patients in relation to influenza infection or pandemic vaccination in Norway. The entire Norwegian population in the years 2008-2014 was defined as our study population (N = 5,219,296). Information on MS diagnosis, influenza infection and vaccination were provided by Norwegian national registries. The self-controlled case series method was used to estimate incidence rate ratios (IRRs) with 95% confidence intervals (95% CI) in defined risk periods. 6755 MS patients were identified during the study period. Average age at first registration of an MS diagnosis was 51.8 years among men and 49.9 years among females (66.9%). The IRR for emergency hospitalization among MS patients the first week after an influenza diagnosis was 3.4 (95% CI 2.4-4.8). The IRR was 5.6 (95% CI 2.7-11.3) after pandemic influenza, and 4.8 (95% CI 3.1-7.4) after seasonal influenza. Pandemic vaccination did not influence risk of hospitalization [IRR within the first week: 0.7 (95% CI 0.5-1.0)]. Among MS patients, influenza infection was associated with increased risk for acute hospitalization while no increased risk was observed after pandemic vaccination. Influenza vaccination could prevent worsening of MS-related symptoms as well as risk of hospitalization.
Identifiants
pubmed: 31873811
doi: 10.1007/s10654-019-00595-2
pii: 10.1007/s10654-019-00595-2
pmc: PMC7222066
doi:
Substances chimiques
Influenza Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
355-362Subventions
Organisme : Reseach Council of Norway
ID : 262700
Références
J Neurol. 2017 Jun;264(6):1035-1050
pubmed: 27604618
PLoS One. 2012;7(1):e30018
pubmed: 22253862
Eur J Neurol. 2013 Aug;20(8):1153-60
pubmed: 23496086
Neurology. 2012 Jun 12;78(24):1986-91
pubmed: 22581930
J Neurol Sci. 1998 Jul 15;159(1):51-3
pubmed: 9700703
N Engl J Med. 2013 Jan 24;368(4):333-40
pubmed: 23323868
J Neurol Sci. 2012 Mar 15;314(1-2):102-3
pubmed: 22056469
CNS Neurosci Ther. 2019 Feb;25(2):245-254
pubmed: 30044050
CNS Drugs. 2015 Mar;29(3):229-44
pubmed: 25761739
Neurology. 2002 Dec 24;59(12):1837-43
pubmed: 12499473
Brain. 2002 May;125(Pt 5):952-60
pubmed: 11960885
Stat Med. 2006 May 30;25(10):1768-97
pubmed: 16220518
Influenza Other Respir Viruses. 2019 May;13(3):240-247
pubmed: 30637942
BMJ. 2016 Sep 12;354:i4515
pubmed: 27618829
Basic Clin Pharmacol Toxicol. 2010 Feb;106(2):86-94
pubmed: 19961477
Am J Manag Care. 2012 Nov;18(11):735-42
pubmed: 23198715
Int J Epidemiol. 2017 Oct 1;46(5):1618-1626
pubmed: 29024996
Lancet. 2008 Oct 25;372(9648):1502-17
pubmed: 18970977
Neurology. 2014 Sep 2;83(10):929-37
pubmed: 25085638
Mult Scler. 2011 Jun;17(6):672-80
pubmed: 21212088
Neurology. 2006 Aug 22;67(4):652-9
pubmed: 16870812
Tidsskr Nor Laegeforen. 2012 Jun 12;132(11):1336-40
pubmed: 22717858
Vaccine. 2017 Apr 4;35(15):1879-1885
pubmed: 28302408
Euro Surveill. 2012 Apr 19;17(16):
pubmed: 22551462
Iran J Neurol. 2016 Apr 3;15(2):109-10
pubmed: 27326369
J Neurol. 2011 Jul;258(7):1197-206
pubmed: 21431896
N Engl J Med. 2017 Jan 19;376(3):209-220
pubmed: 28002688
Brain Behav. 2019 Nov;9(11):e01422
pubmed: 31583850